The structure and biological features of fibrinogen and fibrin

Annals of the New York Academy of Sciences

Volumn 936, Issue , 2001, Pages 11-30

  Mosesson, Michael W ^a   Siebenlist, Kevin R ^b   Meh, David A ^a  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b MARQUETTE UNIVERSITY   (United States)

Author keywords

Crosslinking; Endothelial cells; Factor XIII; Fibrin; Fibrinogen; Fibrinolysis; Integrins; Leukocytes; Platelets

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 13; CELL RECEPTOR; ENZYME INHIBITOR; ENZYME PRECURSOR; FIBRIN; FIBRINOGEN; FIBRINOPEPTIDE B; INTEGRIN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

BINDING SITE; BLOOD CLOTTING; CELL INTERACTION; CONFERENCE PAPER; ENDOTHELIUM CELL; FIBRIN POLYMERIZATION; FIBRINOLYSIS; FIBROBLAST; HUMAN; INFLAMMATION; LEUKOCYTE; NEOPLASM; NONHUMAN; PROTEIN CROSS LINKING; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; THROMBOCYTE; WOUND HEALING;

EID: 0034964447     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb03491.x     Document Type: Conference Paper

References (145)

1. Covalent structure of fibrinogen
2. 2-terminal part of human fibrinogen
3. The role of amino-terminal disulfide bonds in the structure and assembly of human fibrinogen
4. Identification of Bβ chain domains involved in human fibrinogen assembly
5. Dimeric half-molecules of human fibrinogen are joined through disulfide bonds in an antiparallel orientation
6. Identification and mass analysis of human fibrinogen molecules and their domains by scanning transmission electron microscopy
7. Morphology of fibrinogen monomers and fibrin polymers
8. Two fold symmetry of human fibrinogen proved at the β chain distal domains by monoclonal-immunoelectron microscopy and image analysis
9. γ and γ′ chains of human fibrinogen are produced by alternative mRNA processing
10. Human fibrinogen heterogeneities. III. Identification of γ chain variants
11. Carboxy-terminal amino acid sequence of a human fibrinogen γ chain variant (γ′)
12. The amino acid sequences in fibrin responsible for high affinity thrombin binding
13. Plasma factor XIII binds specifically to fibrinogen molecules containing γ′ chains
14. Characterization of the γ chain platelet binding site on fibrinogen fragment D
15. Exposure of platelet fibrinogen receptors by ADP and epinephrine
16. Recognition site for the platelet receptor is present on the 15-residue carboxy-terminal fragment of the γ-chain of human fibrinogen and is not involved in the fibrin polymerization reaction
17. Human platelets possess an inducible and saturable receptor specific for fibrinogen
18. The fibrinogen-fibrin conversion
19. Studies on the action of thrombotic enzymes on bovine fibrinogen as measured by N-terminal analysis
20. A two-step fibrinogen-fibrin transition in blood coagulation
21. Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization
22. Characterization of fibrinogen New York 1
23. 2-terminus
24. The polymerization and thrombin-binding properties of des-(Bβ1-42)-fibrin
25. Distinctive role of histidine-16 of the Bβ chain of fibrinogen in the end-to-end association of fibrin
26. Photoaffinity labeling of the primary fibrin polymerization site: Isolation of a CNBr fragment corresponding to γ 337-379
27. The primary fibrin polymerization pocket: Three-dimensional structure of a 30-kDa C-terminal γ chain fragment complexed with the peptide gly-pro-arg-pro
28. Crystal structure of fragment double-D from human fibrin with two different bound ligands
29. The mechanism of polymerization of fibrinogen
30. An electron microscopic investigation of the polymerization of bovine fibrin monomer
31. Structure of the fibrin protofibril
32. Identification of covalently linked trimeric and tetrameric D domains in crosslinked fibrin
33. Electron microscope structural study of modified fibrin and a related modified fibrinogen aggregate
34. Evidence for a second type of fibril branch point in fibrin polymer networks, the trimolecular junction
35. Sequence of release of fibrinopeptide A from fibrinogen molecules by thrombin or Atroxin
36. Isolation and characterization of the fibrin intermediate arising from cleavage of one fibrinopeptide A from fibrinogen
37. Fibrin in human plasma: Gel architectures governed by rate and nature of fibrinogen activation
38. Studies on the ultrastructure of fibrin lacking fibrinopeptide B (β-fibrin)
39. The covalent structure of factor XIIIa crosslinked fibrinogen fibrils
40. The role of fibrinogen D domain intermolecular association sites in the polymerization of fibrin and fibrinogen Tokyo II (γ275 Arg→Cys)
41. Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin
42. Fibrinopeptide B in fibrin assembly and metabolism: Physiologic significance in delayed release of the peptide
43. Localization of a fibrin polymerization site complimentary to Gly-His-Arg sequence
44. Location of the binding site "b" for lateral polymerization of fibrin
45. The preparation and properties of human fibrinogen of relatively high solubility
46. Fibrinogen heterogeneity
47. Carboxyl-terminal portions of the α chains of fibrinogen and fibrin
48. Role of the αC domains of fibrin in clot formation
49. Thrombin cleavage enhances exposure of a heparin binding domain in the N-terminus of the fibrin β chain
50. Heparin-binding domain of fibrin mediates its binding to endothelial cells
51. Spreading of platelets on fibrin is mediated by the amino terminus of the β chain including peptide β 15-42
52. Cell proliferation on fibrin: Modulation by fibrinopeptide cleavage
53. Fibrin II induces endothelial cell capillary tube formation
54. Endothelial cell VE-cadherin functions as a receptor for the β15-42 sequence of fibrin
55. Mediation of fibrin-induced release of von Willebrand factor from cultured endothelial cells by the fibrin β chain
56. Endothelial cell responses to fibrin mediated by FPB cleavage and the amino terminus of the β chain
57. Cross-linking of fibrinogen and fibrin by fibrin-stabilizing factor (factor XIIIa)
58. Protransglutaminase (factor XIII) mediated crosslinking of fibrinogen and fibrin
59. γ-γ Cross-linking sites in human and bovine fibrin
60. Hybrid fibrin: Proof of the intermolecular nature of γ-γ crosslinking units
61. Cleavage of fibrin-derived D-dimer into monomers by endopeptidase from puff ader venom (bitis arietans) acting at cross-linked sites of the γ chain. Sequence of carboxy-terminal cyanogen bromide γ-chain fragments
62. a fibrin cross-linking
63. Factor XIIIa-catalyzed cross-linking of recombinant αC fragments of human fibrinogen
64. Immunoelectrophoretic characterizations of the cross-linking of fibrinogen and fibrin by factor XIIIa and tissue transglutaminase
65. Evidence for intramolecular cross-linked Aα γ chain heterodimers in plasma fibrinogen
66. Factors affecting γ-chain multimer formation in cross-linked fibrin
67. Contact with the N termini in the central E domain enhances the reactivities of the distal D domains of fibrin to factor XIIIa
68. Crosslinked fibrinogen dimers demonstrate a feature of the molecular packing in fibrin fibers
69. Determination of the topology of factor XIIIa-induced fibrin γ-chain cross-links by electron microscopy of ligated fragments
70. The complementary aggregation sites of fibrin investigated through examination of polymers of fibrinogen with fragment E
71. Orientation of the carboxy-terminal regions of fibrin γ chain dimers determined from the crosslinked products formed in mixtures of fibrin, fragment D, and factor XIIIa
72. Crystal structure of a 30 kDa C-terminal fragment from the T chain of human fibrinogen
73. The role of the β-strand insert in the central domain of the fibrinogen γ-module
74. Crosslinking of fibrinogen to immobilized des AA-fibrin
75. Chromatography and electron microscopy of cross-linked fibrin polymers-A new model describing the cross-linking at the DD-trans contact of the fibrin molecules
76. Position of γ chain carboxy-terminal regions in fibrinogen: Fibrin crosslinking mixtures
77. The location of the carboxy-terminal region of γ chains in fibrinogen and fibrin D domains
78. On the regulation and control of fibrinolysis
79. Latent tissue plasminogen activator produced by human endothelial cells in culture: Evidence for an enzyme-inhibitor complex
80. Kinetics of the activation of plasminogen by human tissue plasminogen
81. Studies of the kinetics of plasminogen activation by tissue plasminogen activator
82. Evaluation of the factors contributing to fibrin-dependent plasminogen activation
83. The sequence Aα-(154-159) of fibrinogen is capable of accelerating the tPA catalyzed activation of plasminogen
84. The sequence γ-(312-324) is a fibrin-specific epitope
85. Conversion of fibrinogen to fibrin: The mechanism of exposure of tPA- and plasminogen-binding sites
86. Quantitative characterization of the binding of plasminogen to intact fibrin clots, lysine-sepharose, and fibrin cleaved by plasmin
87. Identification and characterization of novel tPA-and plasminogen-binding sites within fibrin(ogen) αC-domains
88. Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis
89. Tissue plasminogen activator and urokinase mediate the binding of glu-plasminogen to plasma fibrin I: Evidence for new binding sites in plasmin-degraded fibrin
90. 2-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor
91. Cross-linking site in fibrinogen for alpha 2-plasmin inhibitor
92. Biochemical and chromatographic studies of certain activities associated with human fibrinogen preparations
93. Coexisting dysfibrinogenemia (γR275C) and factor V Leiden deficiency associated with thromboembolic disease (fibrinogen Cedar Rapids)
94. 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis
95. 2-antiplasmin to fibrin(ogen)
96. Monocyte plasminogen activator inhibitor 2 (PAI-2) inhibits u-PA-mediated fibrin clot lysis and is cross-linked to fibrin
97. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin
98. Lipoprotein(a), fibrin binding, and plasminogen activation
99. Multiple binding with identical linkage: A mechanism that explains the effect of lipoprotein(a) on fibrinolysis
100. Factor XIIIa cross-links lipoprotein(a) with fibrinogen and is present in human atherosclerotic lesions
101. Anion-binding exosite of human α-thrombin and fibrin(ogen) recognition
102. A player of many parts: The spotlight falls on thrombin's structure
103. Note on the adsorption of thrombin on fibrin
104. An antithrombin reaction related to prothrombin activation
105. Dysfibrinogenemia and thrombosis
106. The binding of thrombin by fibrin
107. Identification and characterization of the thrombin binding sites on fibrin
108. Platelet receptor recognition site on human fibrinogen. Synthesis and sturcture-function relationship of peptides corresponding to the C-terminal segment of the γ chain
109. Localization of the binding site on fibrin for the secondary binding site of thrombin
110. A synthetic analog of fibrinogen α27-50 is an inhibitor of thrombin
111. Fibrinogen New York I: The structural, functional, and genetic defects and an hypothesis of the role of fibrin in the regulation of coagulation and fibrinolysis
112. Molecular basis of fibrinogen Naples associated with defective thrombin binding and thrombophilia
113. Strategy for recombinant multichain protein synthesis: Fibrinogen Bβ-chain variants as thrombin substrates
114. Fibrinogen Naples I (BβA68T) non-substrate thrombin binding capacities
115. A role for platelets and thrombin in the juvenile stroke of two siblings with defective thrombin-absorbing capacity of fibrin(ogen)
116. Effects of γ/γA chain fibrin on the plasma thrombin generation in afibrinogenemia
117. Embolized ischemic lesions of toes in an afibrinogenemic patient: Possible relevance to in vivo circulating thrombin
118. Amino acid sequences in fibrinogen mediating its interaction with its platelet receptor, GP IIbIIIa
119. Evidence that arginyl-glycyl-aspartate peptides and fibrinogen γ chain peptides share a common binding site on platelets
120. Competition for related but nonidentical binding sites on the glycoprotein IIb-IIIa complex by peptides derived from platelet adhesive proteins
121. Human endothelial cells synthesize and express an arg-gly-asp-directed adhesion receptor involved in attachment to fibrinogen and yon Willebrand factor
122. Distinct biological consequences of integrin alpha v beta 3-mediated melanoma cell adhesion to fibrinogen and its plasmic fragments
123. 3
124. 3 on their surface
125. Fibrinogen is a ligand for integrin α5β1 on endothelial cells
126. 2 Mac-1) and promotes leukocyte adhesion
127. Interactions among heparin, cold-insoluble globulin, and fibrinogen in formation of the heparin precipitable fraction of plasma
128. Cross-linking of cold-insoluble globulin by fibrin-stabilizing factor
129. Cross-linking of fibronectin to C-terminal fragments of the fibrinogen alpha-chain by factor XIIIa
130. Amino acid sequence of the factor XIIIa acceptor site in bovine plasma fibronectin
131. Binding of basic fibroblast growth factors to fibrinogen and fibrin
132. Potentiation of endothelial cell proliferation by fibrin(ogen)-bound fibroblast growth factor-2
133. Fibrinogen and fibrin protect fibroblast growth factor-2 from proteolytic degradation
134. Insulin-like growth factor-binding protein-3 binds fibrinogen and fibrin
135. Characterization of the binding of factor Xa to fibrinogen/fibrin derivatives and localization of the factor Xa binding site on fibrinogen
136. A novel degradation pathway of tissue factor pathway inhibitor: Incorporation into fibrin clot and degradation by thrombin
137. Quantitative measurement of plasma gelsolin and its incorporation into fibrin clots
138. Interaction of histidine-rich glycoprotein with fibrinogen and fibrin
139. Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as hisitidine-rich glyocoprotein
140. Plasminogen binding by alpha 2-antiplasmin and histidine-rich glycoprotein does not inhibit plasminogen activation at the surface of fibrin
141. Familial association of high levels of histidine-rich glycoprotein and plasminogen activator inhibitor-1 with venous thromboembolism
142. High levels of histidine-rich glycoprotein and thrombotic diathesis
143. Congenital histidine-rich glycoprotein deficiency
144. A new case of hereditary histidine-rich glycoprotein deficiency with familial thrombophila